Ziprasidone - Not an option for serotonin syndrome [6]

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 11, 2003, Pages 1147-1148

  Cates, Marshall E ^a  

^a SAMFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYPROHEPTADINE; METHYSERGIDE; PROPRANOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; ZIPRASIDONE;

DISEASE EXACERBATION; DRUG MECHANISM; DRUG USE; HUMAN; LETTER; NEUROTRANSMISSION; RECEPTOR BLOCKING; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM;

EID: 0344082832     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Birmes P, Coppin D, Schmitt L, Lauque D. Serotonin syndrome: a brief review. CMAJ 2003;168(11):1439-42.
2. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 2000;68:29-39.
3. Green B. Focus on ziprasidone. Curr Med Res Opin 2001;17:146-50.
4. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychoric drug. Pharmacotherapy 2001;21:717-30.
5. Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotics. Am J Psychiatry 2002;159:672-73.
6. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.